Assessment of haemophilia treatment practice pattern in Japan

Haemophilia

Volumn 15, Issue 5, 2009, Pages 1032-1038

  Ono, Orie ^a   Suzuki, Y ^b   Yosikawa, K ^c   Wada, I ^d   Doi, Y ^e   Takano, M ^f   Wada, Y ^g   Fukushima, K ^h  

^a School of Medicine   (Japan)

^b TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE HOSPITAL   (Japan)

^d Ogikubo Hospital   (Japan)

^e SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

^f NAGOYA UNIVERSITY HOSPITAL   (Japan)

^g NARA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^h HYOGO COLLEGE OF MEDICINE HOSPITAL   (Japan)

Author keywords

Adherence; Haemophilia A; Haemophilia B; Nurses; On demand; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATTITUDE TO HEALTH; CHILD; CONTROLLED STUDY; DISEASE CLASSIFICATION; FAMILY ATTITUDE; HEALTH SURVEY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; INFUSION SYSTEM; JAPAN; MAJOR CLINICAL STUDY; NURSE ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RISK FACTOR; SCORING SYSTEM;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; HEALTH CARE SURVEYS; HEMOPHILIA A; HEMOPHILIA B; HUMANS; JAPAN; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 69949089728     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02041.x     Document Type: Article

References (22)

1. Kasper CK. Concentrate safety efficacy. Haemophilia 2002; 8: 161-5.
2. Ljung R, Aronis-Vournas S, Kurnik-Auberger K et al. Treatment of children with haemophilia in Europe: A survey of 20 centers in 16 countries. Haemophilia 2000; 6: 619-24.
3. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J. Intern Med 1992; 232: 25-32.
4. Plug I, van der Bom JG, Peters M et al. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood 2004; 104: 3494-500.
5. Royal S, Schramm W, Berntorp E et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002; 8: 44-50.
6. Yee TT, Beeton K, Griffoen A et al. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 2002; 8: 76-82.
7. Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003; 9: 272-8.
8. Manco-Johnson MJ, Rioke B, Kasper CK. Advances in case of children with hemophilia. Semin Thromb Hemost 2003; 29: 585-94.
9. Steen Carlsson K, Hojgard S, Glomstein A et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003; 9: 555-66.
10. Van den Berg HM, Dunn A, Fisher K, Blanchette VS. Prevention and treatment of musculoskeletal disease in the haemophilia population: Role of prophylaxis and synovectomy. Haemophilia 2006; 3: 159-68.
11. Van den Berg HM, Fischer K, Mauser-Bunschoten EP et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-5.
12. Fischer K, van den Bom JG, Molho P et al. Prophylactic versus on-demand strategies for severe haemophilia: A comparison of costs and long-term outcome. Haemophilia 2002; 8: 745-52.
13. Van den Berg HM, Fischer K, Vander Bom JG. Comparing outcome of different treatment regimens for severe haemophilia. Haemophilia 2003; 9(Suppl. 1):27-31.
14. Lippert B, Berger K, Berntorp E et al. Cost effectiveness of haemophilia treatment; a cross-national assessment. Blood Coagul Fibrinolysis 2005; 16: 477-85.
15. Giangrande PL. Adverse events in the prophylaxis of haemophilia. Haemophilia 2003; 9(Suppl. 1): 50-6.
16. Morado M, Villar A, Jimenez Yuste V, Quintana M, Hernandez Navarro F. Prophylactic treatment effects on inhibitor risk: Experience in one centre. Haemophilia 2005; 11: 79-83.
17. Astermark J. When to start and when to stop primary prophylaxis in patients with severe primary prophylaxis in patients with severe haemophilia. Haemophilia 2003; 9 (Suppl. 1): 32-7.
18. Butler RB, Mcclure W, Wulff K. Practice patterns in haemophilia A therapy - a survey of treatment centers in the United States. Haemophilia 2003; 9: 549-54.
19. Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy -global progress towards optimal care. Haemophilia 2006; 12: 75-81.
20. Christie B, Khair K, Lawrence K, Butler R, O'shea E. Assessment of haemophilia A treatment practice patterns: A global nurse perspective. Haemophilia 2006; 12(Suppl. 2): 93.
21. Shirahata A, Ono O. Current status of hemophilia nurses coordinator in Japan. J Pediatr Hematol 2003; 17: 58-66.
22. Shirahata A, Ono O, Yanaga Y. Comprehensive care for hemophiliacs - activities of North Kyushu Hemophilia Center at the University Hospital of Occupational and Environmental Health, Japan. J UOEH 1996; 18: 141-50.